ITEM 7.01 REGULATION FD DISCLOSURE

On January 7, 2021, Zymeworks Inc. ("Zymeworks") issued a press release announcing that: (i) management will present at the upcoming 39th Annual J.P. Morgan Healthcare Conference and (ii) Zymeworks will host two webcasts in January to discuss the zanidatamab clinical data presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and provide an update on ZW49's clinical progress.

On January 7, 2021, Zymeworks filed this press release with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com. A copy of this press release is attached as Exhibit 99.1 hereto.

The information provided under this Item (including Exhibit 99.1, attached hereto) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS




(d) Exhibits



Exhibit
  No.     Description

99.1        Press Release dated January 7, 2021.

104       Cover Page Interactive Data File (embedded as Inline XBRL document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses